Spots Global Cancer Trial Database for zevalin
Every month we try and update this database with for zevalin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas. | NCT00354822 | Lymphoma, Non-H... | Zevalin | 18 Years - 70 Years | A.O. Ospedale Papa Giovanni XXIII | |
| Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy | NCT00850512 | Diffuse Large B... | CHOP21-R Zevalin | 60 Years - | University of Bologna | |
| Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) | NCT00607854 | Diffuse Large B... Mantle Cell Lym... | Ibritumomab Tiu... | 18 Years - 65 Years | University Hospital, Bordeaux | |
| Zevalin Post-marketing Surveillance in Japan | NCT01448928 | Non-Hodgkin's L... | [90]Y-ibritumom... | - | Spectrum Pharmaceuticals, Inc | |
| Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma | NCT00387023 | Non-Hodgkin's L... Lymphoma | Rituximab Zevalin | 18 Years - | M.D. Anderson Cancer Center | |
| Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas | NCT00493454 | Lymphoma | Zevalin Rituximab ^111 In Ibritum... | 18 Years - | M.D. Anderson Cancer Center | |
| Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma | NCT00514475 | Mantle Cell Lym... | 90Y-ibritumomab... | 18 Years - 65 Years | Oslo University Hospital | |
| Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies | NCT00048737 | Lymphoma Leukemia | Zevalin Radioim... Rituximab Fludarabine Cyclophosphamid... Allogeneic Stem... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas | NCT00521560 | Primary Non-Hod... Refractory Non-... CD20+ Aggressiv... | Zevalin | 18 Years - 65 Years | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | |
| Zevalin-beam for Aggressive Lymphoma | NCT00491491 | Non-Hodgkin's L... | ibritumomab tiu... BEAM chemothera... | 18 Years - 70 Years | Sheba Medical Center | |
| Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma | NCT01549886 | Non-Hodgkin's L... | Y-90-Zevalin Moxtezafin Gado... Rituximab | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation | NCT00591630 | Diffuse Large C... Lymphoma | Zevalin Carmustine Etoposide Cytarabine Melphalan Rituximab Stem Cell Trans... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma | NCT00119730 | Mantle Cell Lym... | Fludarabine Mitoxantrone Rituximab Zevalin | 18 Years - | Dana-Farber Cancer Institute | |
| Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma | NCT00438581 | Non-Hodgkin's L... | Yttrium 90 Ibri... | 18 Years - 70 Years | McGill University | |
| Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma | NCT00119730 | Mantle Cell Lym... | Fludarabine Mitoxantrone Rituximab Zevalin | 18 Years - | Dana-Farber Cancer Institute | |
| Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT | NCT02992223 | Refractory B-Ce... Recurrent B-Cel... | 19 Years - | Azienda Ospedaliera Città della Salute e della Scienza di Torino | ||
| Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma | NCT00290511 | Lymphoma | Fludarabine Mitoxantrone Rituximab Zevalin Dexamethasone | 60 Years - | M.D. Anderson Cancer Center | |
| A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen | NCT00319332 | Lymphoma, Small... Lymphoma, Large... Lymphoma, Folli... Lymphoma, Non-H... | Ibritumomab Tiu... Iodine I 131 To... | 18 Years - | GlaxoSmithKline | |
| Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma | NCT01207765 | Multiple Myelom... | indium-111-ibri... 90Y Zevalin | 18 Years - 70 Years | Tufts Medical Center | |
| A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) | NCT01827605 | Relapsed Follic... | ZEVALIN BEAM | 18 Years - 65 Years | Fondazione Italiana Linfomi - ETS | |
| Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma | NCT00514475 | Mantle Cell Lym... | 90Y-ibritumomab... | 18 Years - 65 Years | Oslo University Hospital | |
| Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma | NCT00386321 | Diffuse Large B... | Yttrium 90 -lab... | 18 Years - 75 Years | Chulalongkorn University | |
| Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas | NCT00493454 | Lymphoma | Zevalin Rituximab ^111 In Ibritum... | 18 Years - | M.D. Anderson Cancer Center | |
| Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma | NCT00514475 | Mantle Cell Lym... | 90Y-ibritumomab... | 18 Years - 65 Years | Oslo University Hospital | |
| External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma | NCT00271050 | Lymphoma, B-Cel... | external beam r... | 18 Years - | The Cleveland Clinic | |
| Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas. | NCT00354822 | Lymphoma, Non-H... | Zevalin | 18 Years - 70 Years | A.O. Ospedale Papa Giovanni XXIII | |
| Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas | NCT00493467 | Lymphoma | Ibritumomab Tiu... Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma | NCT01549886 | Non-Hodgkin's L... | Y-90-Zevalin Moxtezafin Gado... Rituximab | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma | NCT00438581 | Non-Hodgkin's L... | Yttrium 90 Ibri... | 18 Years - 70 Years | McGill University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
